Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2021

Takahashi Toshiaki, Umeguchi Hitomi, Tateishi Akiko, Yoshida Tatsuya, Motoi Noriko, Ohe Yuichiro

Abstract excerpt

OBJECTIVES: Rapid tumor progression occurring after the discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy is referred to as a disease flare of non-small cell lung cancer (NSCLC). The clinicopathological features of disease flares after osimertinib discontinuation remain unclear. RESULTS: We report a patient with EGFR-mutated NSCLC who experienced the progression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33276184
DOI: 10.1016/j.lungcan.2020.11.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.PMID 33276184Read ↗

Disease flare after gefitinib discontinuation.Semantic proximity Read ↗

Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S.Semantic proximity Read ↗

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.Semantic proximity Read ↗

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.Semantic proximity Read ↗

Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series.Semantic proximity Read ↗

Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer.Semantic proximity Read ↗

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.Semantic proximity Read ↗

Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.Semantic proximity Read ↗

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.Semantic proximity Read ↗

Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support.Semantic proximity Read ↗

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.